Perimenopause and Cardiovascular Health: What Every Woman Should Know

Cardiovascular disease is the leading cause of death in women globally — and perimenopause is when risk begins to change significantly. Here is what to know and what to do.

Cardiovascular disease kills more women globally than any other cause — more than all cancers combined. Yet the conversation about perimenopause and heart health is almost entirely absent from mainstream discussions of the transition. Women are told about hot flushes, brain fog, and mood changes. They are rarely told that their cardiovascular risk profile is actively changing during perimenopause, and that the actions taken during this window have greater long-term impact than equivalent actions taken years later.

What Oestrogen Does for the Heart

Oestrogen is cardioprotective through multiple well-documented mechanisms. It maintains healthy cholesterol ratios by increasing HDL ("good" cholesterol, which transports cholesterol to the liver for disposal) and reducing LDL ("bad" cholesterol, which deposits on arterial walls). It promotes arterial flexibility and elasticity — arteries that maintain their elasticity are significantly less likely to develop atherosclerosis. It has anti-inflammatory effects on the endothelium (blood vessel walls), and vascular inflammation is a central mechanism in atherosclerotic disease. It supports nitric oxide production, which causes blood vessels to relax and widen, reducing blood pressure. And it directly influences insulin sensitivity in ways that affect the metabolic risk factors for cardiovascular disease.

When oestrogen declines during perimenopause, all of these protective mechanisms weaken simultaneously. The cardiovascular risk profile that oestrogen has maintained throughout the reproductive years begins to shift: LDL rises, HDL falls, arterial stiffness increases, blood pressure tends to rise, inflammatory markers increase, and insulin sensitivity decreases. These are not dramatic events — they are gradual shifts in a risk trajectory that builds over years and decades. But they begin during perimenopause, which is exactly why this is the most important window for protective action.

Perimenopause Heart Palpitations

Heart palpitations — the awareness of the heartbeat as rapid, irregular, or forceful — are a common perimenopause symptom that causes significant anxiety. Most perimenopause palpitations are benign, caused by the effect of oestrogen fluctuation on the autonomic nervous system. They may occur at rest, during mild activity, or on waking from sleep. They are typically brief, non-sustained, and not accompanied by chest pain or breathlessness.

Palpitations that are sustained, accompanied by chest pain or shortness of breath, or associated with feeling faint warrant prompt clinical assessment. While these features are present in the minority of palpitations that indicate underlying cardiac pathology, the symptom overlap between perimenopause and cardiac arrhythmia means that more concerning presentations should be assessed rather than assumed to be benign.

If palpitations are frequent or distressing, raising them with your GP is appropriate — both to rule out cardiac causes and because HRT often significantly reduces them by stabilising the autonomic nervous system effects of oestrogen fluctuation.

HRT and Cardiovascular Outcomes — What the Current Evidence Shows

The relationship between HRT and cardiovascular health was significantly confused by the misinterpretation of the 2002 Women's Health Initiative study, which produced findings that were widely applied to populations for whom they were not relevant. The current evidence — from the WHI reanalysis, the SWAN cohort, the Cache County Study, and other longitudinal research — tells a considerably more favourable story.

HRT started during perimenopause or within ten years of the final menstrual period is associated with reduced cardiovascular risk in the current evidence base. The timing hypothesis — that oestrogen's cardioprotective effects are most significant when HRT is initiated close to the onset of hormonal decline — is well-supported. The WHI findings that produced alarming cardiovascular signals were produced in a population of women who began HRT on average over a decade past menopause — a different clinical situation from perimenopause management.

For women considering HRT during perimenopause, the cardiovascular benefit of early initiation is a meaningful additional argument in favour of treatment — one that is rarely communicated with the same clarity as cardiovascular risks that are sometimes cited against it.

Protective Actions — What Has the Most Impact

Aerobic exercise is the most evidence-supported non-prescription cardiovascular protective intervention. One hundred and fifty minutes of moderate-intensity aerobic activity per week — the UK physical activity guideline — is associated with significant reductions in cardiovascular risk, improvements in cholesterol profiles, blood pressure reduction, and improved arterial elasticity. This guideline is relevant to all adults, but its importance is elevated during perimenopause as the natural cardiovascular protection of oestrogen withdraws.

Resistance training adds independent cardiovascular benefits — improving insulin sensitivity, reducing abdominal visceral fat, and supporting healthy metabolic function. Blood pressure monitoring is worth establishing during perimenopause, particularly if you have a family history of hypertension: home monitoring (weekly or fortnightly readings) provides better information than annual clinical measurement and gives early warning of changes warranting clinical attention.

Cholesterol monitoring during perimenopause is reasonable, particularly for women with cardiovascular risk factors. Not smoking — or stopping if you currently smoke — has dramatic cardiovascular risk reduction effects at any age. Limiting alcohol moderately supports blood pressure management. And the Mediterranean dietary pattern — high in vegetables, whole grains, legumes, fish, and olive oil — has the strongest evidence base for long-term cardiovascular protection.